Geneva, 13 December 2019 – Tumor mutational burden (TMB) is an emerging complex biomarker that is promising to be predictive for positive response to immunotherapy/checkpoint inhibitor drugs in patients diagnosed with cancer. Different approaches in testing technology made it desirable to standardize and harmonize TMB determination. NEO New Oncology supports these quality assurance efforts and has participated in the initiative of QuIP and Friends of Cancer Research to harmonize TMB determination.
The results of the harmonization study presented in Geneva today showed that the NEOplus v2 RUO* test is suitable for the reliable determination of tumor mutational load. When analyzing 20 samples in 5 different laboratories, the TMB values detected with NEOplus v2 RUO* showed an excellent correlation with the TMB determination using WES (p = 0.84, R = 0.99). The evaluation confirms that the complete solution consisting of Hybrid-Capture-Technology and specialized bioinformatics enables reliable use in the laboratory.
*For research use only. Not for use in diagnostic procedures.